Z. Xue

发表

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

K. King, Chun-Fang Xu, L. Cardon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

Chun-Fang Xu, L. Cardon, V. Mooser, 2010, British Journal of Cancer.

Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).

K. King, Chun-Fang Xu, R. Figlin, 2014 .

IL 8 polymorphisms and overall survival in pazopanib-or sunitinib-treated patients with renal cell carcinoma

J. Whittaker, R. Motzer, T. Choueiri, 2017 .

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

J. Whittaker, R. Motzer, T. Choueiri, 2015, British Journal of Cancer.

Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.

R. Motzer, L. Pandite, K. Deen, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

K. King, M. Nelson, Chun-Fang Xu, 2015, Clinical Cancer Research.

Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.

Chun-Fang Xu, L. Cardon, M. Barnes, 2011, Journal of Hepatology.

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.

K. King, N. Bing, V. Mooser, 2012 .

Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study).

Chun-Fang Xu, R. Motzer, T. Choueiri, 2013 .

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.

K. King, N. Bing, V. Mooser, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

K. King, M. Nelson, Chun-Fang Xu, 2015, Clinical Cancer Research.

Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms.

Chun-Fang Xu, R. Motzer, T. Choueiri, 2013 .

Association of germ-line SNPs with overall survival (OS) in pazopanib-treated patients (Pts) with advanced renal cell carcinoma (RCC).

K. King, J. Whittaker, N. Bing, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.